

# Massimiliano Di Filippo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3662483/publications.pdf>

Version: 2024-02-01

105  
papers

6,746  
citations

81743

39  
h-index

66788

78  
g-index

106  
all docs

106  
docs citations

106  
times ranked

10153  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends in Neurosciences, 2007, 30, 211-219.	4.2	707
2	Neurofilament light chain as a biomarker in neurological disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 870-881.	0.9	623
3	Direct and indirect pathways of basal ganglia: a critical reappraisal. Nature Neuroscience, 2014, 17, 1022-1030.	7.1	598
4	Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurology, The, 2010, 9, 1106-1117.	4.9	329
5	A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurology, The, 2006, 5, 974-983.	4.9	289
6	Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. Trends in Pharmacological Sciences, 2008, 29, 402-412.	4.0	172
7	New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease. Lancet Neurology, The, 2013, 12, 811-821.	4.9	165
8	Distinct Levels of Dopamine Denervation Differentially Alter Striatal Synaptic Plasticity and NMDA Receptor Subunit Composition. Journal of Neuroscience, 2010, 30, 14182-14193.	1.7	155
9	Effects of central and peripheral inflammation on hippocampal synaptic plasticity. Neurobiology of Disease, 2013, 52, 229-236.	2.1	155
10	Multiple sclerosis and cognition: synaptic failure and network dysfunction. Nature Reviews Neuroscience, 2018, 19, 599-609.	4.9	151
11	The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D <sub>2</sub> /A <sub>2A</sub> Receptor Interaction in the Striatum: Implications for Parkinson's Disease. Journal of Neuroscience, 2011, 31, 1850-1862.	1.7	140
12	Plasticity and repair in the post-ischemic brain. Neuropharmacology, 2008, 55, 353-362.	2.0	132
13	Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain, 2011, 134, 375-387.	3.7	125
14	Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. Brain, 2012, 135, 1884-1899.	3.7	124
15	Mitochondria and the Link Between Neuroinflammation and Neurodegeneration. Journal of Alzheimer's Disease, 2010, 20, S369-S379.	1.2	118
16	Short-term and long-term plasticity at corticostriatal synapses: Implications for learning and memory. Behavioural Brain Research, 2009, 199, 108-118.	1.2	115
17	Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18985-18990.	3.3	113
18	A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimer's Research and Therapy, 2018, 10, 8.	3.0	111

#	ARTICLE	IF	CITATIONS
19	Multiple Mechanisms Underlying the Neuroprotective Effects of Antiepileptic Drugs Against In Vitro Ischemia. <i>Stroke</i> , 2006, 37, 1319-1326.	1.0	95
20	Sensitization, glutamate, and the link between migraine and fibromyalgia. <i>Current Pain and Headache Reports</i> , 2007, 11, 343-351.	1.3	95
21	Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration. <i>Brain</i> , 2019, 142, 1365-1385.	3.7	82
22	Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 204-208.	0.9	79
23	Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit. <i>Biological Psychiatry</i> , 2016, 79, 402-414.	0.7	77
24	Ischemic Stroke Injury Is Mediated by Aberrant Cdk5. <i>Journal of Neuroscience</i> , 2014, 34, 8259-8267.	1.7	73
25	Epilepsy, amyloid- $\beta^2$ , and D1 dopamine receptors: a possible pathogenetic link?. <i>Neurobiology of Aging</i> , 2016, 48, 161-171.	1.5	71
26	Hippocampal Synaptic Plasticity, Memory, and Epilepsy: Effects of Long-Term Valproic Acid Treatment. <i>Biological Psychiatry</i> , 2010, 67, 567-574.	0.7	68
27	Persistent activation of microglia and NADPH oxidase drive hippocampal dysfunction in experimental multiple sclerosis. <i>Scientific Reports</i> , 2016, 6, 20926.	1.6	68
28	Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon- $\beta^2$ 1a, and high doses of immunoglobulins. <i>Multiple Sclerosis Journal</i> , 2007, 13, 313-331.	1.4	58
29	Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3848-3857.	3.3	58
30	Electrophysiology and Pharmacology of Striatal Neuronal Dysfunction Induced by Mitochondrial Complex I Inhibition. <i>Journal of Neuroscience</i> , 2008, 28, 8040-8052.	1.7	54
31	mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 448-450.	0.9	53
32	Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients. <i>Neuroscience Letters</i> , 2008, 435, 223-228.	1.0	52
33	The Endocannabinoid System in Parkinsons Disease. <i>Current Pharmaceutical Design</i> , 2008, 14, 2337-2346.	0.9	52
34	Synaptic plasticity, dopamine and Parkinson's disease: one step ahead. <i>Brain</i> , 2008, 132, 285-287.	3.7	50
35	CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 1023-1037.	4.0	48
36	Beyond clinical changes: Rehabilitation-induced neuroplasticity in MS. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1348-1362.	1.4	47

#	ARTICLE	IF	CITATIONS
37	â€œBetter explanationsâ€•in multiple sclerosis diagnostic workup. <i>Neurology</i> , 2019, 92, e2527-e2537.	1.5	44
38	Endogenous 17 $\beta$ -estradiol is required for activity-dependent long-term potentiation in the striatum: interaction with the dopaminergic system. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 192.	1.8	43
39	Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2007, 188, 146-158.	1.1	41
40	Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. <i>Journal of Neurology</i> , 2019, 266, 2157-2163.	1.8	41
41	Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis. <i>Cell Reports</i> , 2021, 37, 110094.	2.9	38
42	2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. <i>Journal of Neurology</i> , 2018, 265, 2684-2687.	1.8	35
43	Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 157.	2.2	35
44	CSF proteome analysis in multiple sclerosis patients by two-dimensional electrophoresis. <i>European Journal of Neurology</i> , 2008, 15, 998-1001.	1.7	34
45	New synaptic and molecular targets for neuroprotection in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 51-60.	2.2	34
46	Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics. <i>Cells</i> , 2021, 10, 1930.	1.8	34
47	Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2020, 339, 577108.	1.1	31
48	Plastic abnormalities in experimental Huntington's disease. <i>Current Opinion in Pharmacology</i> , 2007, 7, 106-111.	1.7	30
49	Synaptic plasticity and experimental autoimmune encephalomyelitis: implications for multiple sclerosis. <i>Brain Research</i> , 2015, 1621, 205-213.	1.1	30
50	Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 123-133.	1.5	30
51	Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2106-2111.	1.4	30
52	Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study. <i>European Journal of Neurology</i> , 2020, 27, 633-643.	1.7	29
53	Impaired Plasticity at Specific Subset of Striatal Synapses in the Ts65Dn Mouse Model of Down Syndrome. <i>Biological Psychiatry</i> , 2010, 67, 666-671.	0.7	28
54	Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis. <i>Neurobiology of Disease</i> , 2018, 113, 97-108.	2.1	27

#	ARTICLE	IF	CITATIONS
55	Epilepsy-induced abnormal striatal plasticity in Bassoon mutant mice. <i>European Journal of Neuroscience</i> , 2009, 29, 1979-1993.	1.2	26
56	Acetyl-L-Carnitine selectively prevents post-ischemic LTP via a possible action on mitochondrial energy metabolism. <i>Neuropharmacology</i> , 2008, 55, 223-229.	2.0	25
57	A multicenter observational analysis of Persistence to Treatment in the new multiple sclerosis era: the RESPECT study. <i>Journal of Neurology</i> , 2018, 265, 1174-1183.	1.8	23
58	Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers. <i>Neural Regeneration Research</i> , 2021, 16, 36.	1.6	23
59	Pathways of neurodegeneration and experimental models of basal ganglia disorders: Downstream effects of mitochondrial inhibition. <i>European Journal of Pharmacology</i> , 2006, 545, 65-72.	1.7	22
60	ACh/Dopamine Crosstalk in Motor Control and Reward: A Crucial Role for $\alpha 6$ -Containing Nicotinic Receptors?. <i>Neuron</i> , 2008, 60, 4-7.	3.8	22
61	Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2018, 118, 1-8.	2.1	22
62	Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 228-232.	0.9	20
63	Hippocampal epileptogenesis in autoimmune encephalitis. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2261-2269.	1.7	20
64	Hippocampal neuroplasticity and inflammation: relevance for multiple sclerosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017, 2, .	1.1	19
65	Low doses of Perampanel protect striatal and hippocampal neurons against in vitro ischemia by reversing the ischemia-induced alteration of AMPA receptor subunit composition. <i>Neurobiology of Disease</i> , 2020, 140, 104848.	2.1	19
66	Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain. <i>Frontiers in Neuroscience</i> , 2021, 15, 672954.	1.4	19
67	A2A Adenosine Receptor Antagonism Enhances Synaptic and Motor Effects of Cocaine via CB1 Cannabinoid Receptor Activation. <i>PLoS ONE</i> , 2012, 7, e38312.	1.1	18
68	A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band. <i>Journal of Neurology</i> , 2017, 264, 973-978.	1.8	18
69	Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study. <i>Journal of Neurology</i> , 2021, 268, 2922-2932.	1.8	18
70	Interferon- $\beta 1a$ protects neurons against mitochondrial toxicity via modulation of STAT1 signaling: Electrophysiological evidence. <i>Neurobiology of Disease</i> , 2014, 62, 387-393.	2.1	17
71	Lower urinary tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of multiple sclerosis. <i>European Journal of Neurology</i> , 2014, 21, 648-653.	1.7	17
72	Interferon- $\beta 1a$ modulates glutamate neurotransmission in the CNS through CaMKII and GluN2A-containing NMDA receptors. <i>Neuropharmacology</i> , 2016, 100, 98-105.	2.0	17

#	ARTICLE	IF	CITATIONS
73	Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4440.	1.8	17
74	Synaptic Dysfunction in Multiple Sclerosis: A Red Thread from Inflammation to Network Disconnection. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9753.	1.8	17
75	Multitarget disease-modifying therapy in Parkinson's disease?. <i>Lancet Neurology</i> , The, 2015, 14, 975-976.	4.9	16
76	Neuro-Immune Cross-Talk in the Striatum: From Basal Ganglia Physiology to Circuit Dysfunction. <i>Frontiers in Immunology</i> , 2021, 12, 644294.	2.2	16
77	From Synaptic Dysfunction to Neuroprotective Strategies in Genetic Parkinson's Disease: Lessons From LRRK2. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 158.	1.8	15
78	Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101461.	0.9	14
79	Ischemic-LTP in Striatal Spiny Neurons of both Direct and Indirect Pathway Requires the Activation of D1-Like Receptors and NO/Soluble Guanylate Cyclase/cGMP Transmission. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 278-286.	2.4	13
80	Lacosamide protects striatal and hippocampal neurons from in vitro ischemia without altering physiological synaptic plasticity. <i>Neuropharmacology</i> , 2018, 135, 424-430.	2.0	13
81	Heterozygous X-linked adrenoleukodystrophy-associated myelopathy mimicking primary progressive multiple sclerosis. <i>Journal of Neurology</i> , 2011, 258, 323-324.	1.8	12
82	Retinopathy during interferon- $\beta$ treatment for multiple sclerosis: case report and review of the literature. <i>Journal of Neurology</i> , 2016, 263, 422-427.	1.8	12
83	High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline. <i>Journal of the Neurological Sciences</i> , 2017, 379, 236-240.	0.3	12
84	Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. <i>European Journal of Neurology</i> , 2021, 28, 1299-1307.	1.7	12
85	Na <sup>+</sup> /Ca <sup>2+</sup> Exchanger Maintains Ionic Homeostasis in the Peri-Infarct Area. <i>Stroke</i> , 2007, 38, 1614-1620.	1.0	11
86	Brain's traffic lights. <i>Nature</i> , 2010, 466, 449-449.	13.7	10
87	Serum neurofilament light chain as a preclinical marker of neurodegeneration. <i>Lancet Neurology</i> , The, 2019, 18, 1070-1071.	4.9	9
88	Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. <i>Journal of Neurology</i> , 2022, 269, 3301-3307.	1.8	9
89	Infliximab monotherapy for neuro-Behçet's disease: A case report. <i>Journal of the Neurological Sciences</i> , 2014, 347, 389-390.	0.3	8
90	The changing tree in Parkinson's disease. <i>Nature Neuroscience</i> , 2015, 18, 1196-1198.	7.1	7

#	ARTICLE	IF	CITATIONS
91	The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI. <i>Journal of Neurology</i> , 2022, 269, 3129-3135.	1.8	6
92	Visual pathway involvement in multiple sclerosis: Look straight in the eyes. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 217-219.	0.9	5
93	Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes. <i>Journal of Neurology</i> , 2018, 265, 522-529.	1.8	5
94	Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency. <i>European Neurology</i> , 2016, 76, 62-68.	0.6	4
95	Editorial: Cognition in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 751687.	1.1	4
96	Finding a way to preserve mitochondria: new pathogenic pathways in experimental multiple sclerosis. <i>Neural Regeneration Research</i> , 2019, 14, 77.	1.6	4
97	A young patient with type C multiple system atrophy and hereditary hemochromatosis. <i>Journal of Neurology</i> , 2010, 257, 294-295.	1.8	3
98	A pathophysiological link between dystonia, striatal interneurons and neuropeptide Y. <i>Brain</i> , 2013, 136, 1341-1344.	3.7	3
99	Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion. <i>Journal of Neurology</i> , 2016, 263, 1449-1451.	1.8	2
100	Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102394.	0.9	2
101	Inter-Laboratory Concordance of Cerebrospinal Fluid and Serum Kappa Free Light Chain Measurements. <i>Biomolecules</i> , 2022, 12, 677.	1.8	2
102	A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117430.	0.3	1
103	A blood test for Alzheimer's disease: a step forward. <i>Lancet Neurology</i> , The, 2021, 20, 691-693.	4.9	1
104	An "all-wheel drive" proposal to accelerate clinical research in common and rare neurological diseases. <i>Neurological Sciences</i> , 2020, 41, 789-793.	0.9	0
105	Informing MS patients on treatment options: a consensus on the process of consent taking. <i>Neurological Sciences</i> , 2020, 41, 2249-2253.	0.9	0